Literature DB >> 32047093

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice.

Craig Haifer1,2, Colleen R Kelly3, Sudarshan Paramsothy1,4, David Andresen1,2, Lito E Papanicolas5,6, Genevieve L McKew1,4, Thomas J Borody7, Michael Kamm8,9, Samuel P Costello10,11, Jane M Andrews6,12, Jakob Begun13,14, Hiu Tat Chan15, Susan Connor16,17, Simon Ghaly2,17, Paul Dr Johnson9,18, Daniel A Lemberg17,19, Ramesh Paramsothy20, Andrew Redmond13,21, Harsha Sheorey8, David van der Poorten1,22, Rupert W Leong23,4.   

Abstract

OBJECTIVE: Faecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.
DESIGN: For these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
RESULTS: Consensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.
CONCLUSIONS: These FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  zzm321990Clostridioides difficilezzm321990; FMT; faecal microbiota transplantation; inflammatory bowel disease; microbiome therapeutics; stool bank

Year:  2020        PMID: 32047093     DOI: 10.1136/gutjnl-2019-320260

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Efficacy of faecal microbiota transplantation on ulcerative colitis and its effect on gastrointestinal motility and immune function.

Authors:  Dengshun Lei; Hong Xu; Renqun Peng; Mei Yang; Xinghui Li; Wei Zuo; Juhua Gou; Shuangjiang Yu; Min Huang; Hao Liu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Dietary Intakes of Recipients of Faecal Microbiota Transplantation: An Observational Pilot Study.

Authors:  Annabel K Clancy; Christina Lee; Harrison Hamblin; Anoja W Gunaratne; Antoinette LeBusque; Eleanor J Beck; Marie V Dawson; Thomas J Borody
Journal:  Nutrients       Date:  2021-04-28       Impact factor: 5.717

3.  Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment.

Authors:  Colleen R Kelly; Loren A Laine; Gary D Wu
Journal:  Gastroenterology       Date:  2020-08-22       Impact factor: 22.682

Review 4.  Faecal microbiota transplantation: indications, evidence and safety.

Authors:  Wei Ting Soo; Robert V Bryant; Samuel P Costello
Journal:  Aust Prescr       Date:  2020-04-01

Review 5.  The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease.

Authors:  Craig Haifer; Rupert W Leong; Sudarshan Paramsothy
Journal:  Curr Opin Pharmacol       Date:  2020-10-07       Impact factor: 5.547

6.  Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection.

Authors:  Young-Seok Cho
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

7.  Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review.

Authors:  Fengqin Su; Yi Luo; Jian Yu; Jimin Shi; Yanmin Zhao; Mengni Yan; He Huang; Yamin Tan
Journal:  Eur J Med Res       Date:  2021-04-28       Impact factor: 2.175

8.  A comprehensive approach to stool donor screening for faecal microbiota transplantation in China.

Authors:  Jianquan He; Xingxiang He; Yonghui Ma; Luxi Yang; Haiming Fang; Shu Shang; Huping Xia; Guanghui Lian; Hailing Tang; Qizhi Wang; Junping Wang; Zhihui Lin; Jianbo Wen; Yuedong Liu; Chunbao Zhai; Wen Wang; Xueliang Jiang; Ji Xuan; Morong Liu; Shiyun Lu; Xuejun Li; Han Wang; Cong Ouyang; Man Cao; Aiqiang Lin; Bangzhou Zhang; Depei Wu; Ye Chen; Chuanxing Xiao
Journal:  Microb Cell Fact       Date:  2021-11-27       Impact factor: 5.328

9.  Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis.

Authors:  Samuel Paul Costello; Alice Day; Chu K Yao; Robert Venning Bryant
Journal:  BMJ Case Rep       Date:  2020-08-24

10.  Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank.

Authors:  Justin Chen; Amanda Zaman; Bharat Ramakrishna; Scott W Olesen
Journal:  Front Cell Infect Microbiol       Date:  2021-04-15       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.